We study protein quality control across translational models of cancer, cardiovascular disease and neurodegeneration with the goal of defining mechanisms of protein homeostasis and identifying therapeutic targets. Our unified approach is based on the realization that a single cellular machinery, the Hsp90/Hsp70 based chaperone machinery, controls the activity, turnover and trafficking of hundreds of client proteins, and as such plays a critical role in the pathogenesis of these varied disorders. Our goal is to define the mechanism by which this machinery triages unfolded or damaged proteins for degradation in order to develop strategies to achieve therapeutic benefits in disease.
All meetings begin at 1:30 pm
September 10, 2019 – Data Blitz – 5515 BSRB
October 8, 2019 – 5515 BSRB
November 12, 2019 – No Meeting
December 10, 2019 – Andy Lieberman’s Lab – 5515 BSRB
January 14, 2020 – Yoichi Osawa’s Lab – 5515 BSRB
February 11, 2020 – Andrea Thompson – 7530 MSRB 1
March 17, 2020 – Mukesh Nyati – via BlueJeans https://bluejeans.com/476279907
April 14, 2020 – Matthias Truttmann’s Lab – 6340 MSRB 3
May 12, 2020 – Mark Cohen – 6340 MSRB 3
June 9, 2020 – Andy Lieberman’s Lab – 6340 MSRB 3
Andrew Lieberman is the Gerald Abrams Collegiate Professor of Pathology and Director of Neuropathology. His laboratory uses cellular and mouse models to study inherited forms of neurodegeneration in hopes of identifying targets for therapeutic intervention.
Yoichi Osawa is the Warner-Lambert/Parke-Davis Professor in Medicine and Professor of Pharmacology. His laboratory studies the Hsp90 and Hsp70 chaperone machinery in protein quality control with a focus on the ubiquitination and regulation of NO synthases and P450 cytochromes.
Mark S. Cohen
Mark S. Cohen is Associate Chair in Surgery and Associate Professor of Surgery and Pharmacology, Director of the Medical School Pathway of Excellence in Innovation/Entrepreneurship, Innovation Chief for the U of M Cancer Center, and a Principal Investigator in the Translational Oncology Program. His translational/basic laboratory is focused on the development of novel cancer therapeutics as well as improved drug delivery strategies to enhance local/regional drug effect and lower toxicity. This work has focused on novel withanolides, novel selective HSP90 inhibitors, and innovative drug delivery strategies with hyaluronic acid and mimetic HDL nanoparticles for all types of solid tumor malignancies.
Mukesh Nyati’s lab conducts research around understanding EGF-Receptor mediated signaling in tumors. We now know that the clinical effectiveness of kinase-targeted agents has been inconsistent, mainly because of the acquired resistance. It has been shown that EGFR has scaffold/allosteric functions in addition to tyrosine kinase activity. Therapies that induce protein degradation of EGFR remains effective in tumors that acquire resistance to tyrosine kinase inhibitors. Based on our current understanding of TKI resistance and EGFR dimerization we are developing new therapeutic strategies targeting the intracellular dimerization interface of EGFR to induce protein degradation as a potential therapy option for EGFR-driven cancers.